Waratah Pharmaceuticals Inc

Psyence Group Inc. is a life science biotechnology company based in Toronto, Ontario, focused on developing innovative, safe, and effective psychedelic and nature-centered solutions for mental health, particularly in the context of palliative care. The company specializes in natural psilocybin products and medicinal formulations aimed at treating anxiety, depression, and associated ailments within clinical environments. As one of the first federally licensed and ISO 22000 certified facilities for psilocybin cultivation and production, Psyence Group operates under the NASDAQ-listed entity Psyence Biomedical Ltd. The company's team comprises experts in neurology and pharmaceutical product commercialization, alongside a global executive team experienced in capital markets and sustainable growth. Generated from the website

Neural Therapeutics Inc. is an ethnobotanical drug discovery and development company dedicated to researching and developing products utilizing psychoactive plants, notably the San Pedro cactus (Echinopsis pachanoi), which contains mescaline. The company emphasizes the importance of indigenous knowledge in the effective use of whole plant extracts, aiming to honor traditional practices while advancing modern pharmaceutical and nutraceutical applications. With a focus on sustainable practices, Neural Therapeutics follows a research and development roadmap that seeks to create zero waste by fully utilizing the plant's capabilities. Comprised of an experienced leadership team with expertise in environmental science, pharmacology, and corporate finance, the company is well-positioned to explore innovative solutions in the natural products industry. Generated from the website

Revive Therapeutics Ltd is a Toronto-based life sciences company dedicated to the research and development of therapeutics and diagnostics for infectious diseases, mental health, and rare disorders. The company is focused on advancing drug development efforts, leveraging regulatory incentives from the FDA, including Emergency Use Authorization and Breakthrough Therapy designations. Currently, Revive is exploring the use of Bucillamine for potential treatments related to public health emergencies and inflammatory disorders, while also advancing psilocybin-based therapeutics through various programs. Their innovative biosynthetic platform, developed by Dr. Gavin Williams, aims to facilitate the rapid production of natural products like psilocybin using engineered enzymatic pathways in E. coli. Generated from the website